VentriPoint Diagnostics Management

Management criteria checks 2/4

VentriPoint Diagnostics' CEO ist Hugh MacNaught , ernannt in Feb 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.013% der Aktien des Unternehmens, im Wert von CA$4.50K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.9 Jahre bzw. 4.3 Jahre.

Key information

Hugh MacNaught

Chief executive officer

CA$37.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	1.9yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Hugh MacNaught

less than a year

Tenure

CA$37,633

Compensation

Mr. Hugh MacNaught served as an Independent Director at VentriPoint Diagnostics Ltd since September 2020 and serves as its Interim CEO, President & Director since February 2024. He served as an Executive V...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
George Adams	Executive Chairman & Corporate Secretary	13.5yrs	CA$346.83k	0.60% CA$ 216.6k
Hugh MacNaught	Interim CEO	less than a year	CA$37.63k	0.013% CA$ 4.6k
Jimmy Jeon	Chief Financial Officer	less than a year	no data	no data
Hirotaka Katagiri	CTO & Business Development Division Director	3.3yrs	no data	no data
Jim Graba	Application Specialist & Chief Trainer	5.9yrs	no data	no data

1.9yrs

Average Tenure

Erfahrenes Management: VPTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Board Members

Name	Position	Tenure	Compensation	Ownership
George Adams	Executive Chairman & Corporate Secretary	13.5yrs	CA$346.83k	0.60% CA$ 216.6k
Hugh MacNaught	Interim CEO	3.6yrs	CA$37.63k	0.013% CA$ 4.6k
Robert Hodgkinson	Independent Director	4.3yrs	CA$18.14k	1.27% CA$ 460.0k
Samuel Schwartz	Chair of Business Advisory Committee	6.1yrs	no data	no data
Scott D. Solomon	Member of Scientific Advisory Board	12.1yrs	no data	no data
Randy AuCoin	Independent Director	2.3yrs	CA$99.20k	no data
David Sahn	Member of Scientific Advisory Board	no data	no data	no data
Mark Lewin	Member of Scientific Advisory Board	no data	no data	no data
Michael Gatzoulis	Member of Scientific Advisory Board	no data	no data	no data
Richard Krasuski	Member of Scientific Advisory Board	12.9yrs	no data	no data
Fiona Fitzgerald	Independent Director	2.5yrs	CA$113.18k	no data
Gregory Skinner	Member of Board of Clinical Advisors	2.2yrs	no data	no data

4.3yrs

Average Tenure

Erfahrener Vorstand: VPTDie Vorstandsmitglieder gelten als erfahren (4 Jahre durchschnittliche Amtszeit).

VentriPoint Diagnostics Management

Management criteria checks 2/4

Key information

Recent management updates

Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President

VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board

VentriPoint Diagnostics Ltd. Announces Executive Changes

Less than half of directors are independent

Ventripoint Diagnostics Ltd. Announces Appointment of Alvira Macanovic as President

VentriPoint Diagnostics Ltd., Annual General Meeting, Aug 16, 2022

Recent updates

Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President

VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board

New minor risk - Share price stability

VentriPoint Diagnostics Ltd. to Report Q3, 2023 Results on Nov 29, 2023

VentriPoint Diagnostics Ltd. Announces Executive Changes

VentriPoint Diagnostics Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product

New major risk - Share price stability

VentriPoint Diagnostics Ltd. to Report Q1, 2023 Results on May 30, 2023

Less than half of directors are independent

Ventripoint Diagnostics Ltd. Announces Appointment of Alvira Macanovic as President

VentriPoint Diagnostics Ltd. Relocates to New Facility in Toronto

VentriPoint Diagnostics Ltd., Annual General Meeting, Aug 16, 2022

Less than half of directors are independent

Ventripoint Appoints Dr. Gregory Skinner to Board of Clinical Advisors

Less than half of directors are independent

High number of new and inexperienced directors

Executive Chairman & CEO exercised options to buy CA$136k worth of stock.

Full year 2020 earnings released: CA$0.025 loss per share (vs CA$0.052 loss in FY 2019)

New 90-day high: CA$0.56

Ventripoint Diagnostics Ltd.'s Heart Analysis System to Be Used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children

New 90-day high: CA$0.26

New 90-day high: CA$0.23

Independent Director recently sold CA$87k worth of stock

Executive Chairman & CEO exercised options to buy CA$453k worth of stock.

Ventripoint Diagnostics Ltd. Enters into A Collaboration Agreement with the Veterinary Hospital At the North Carolina State University

Kings College London Receives VMS+3.0 Ventripoint Whole Heart Analysis System

Executive Chairman & CEO recently sold CA$210k worth of stock

Ventripoint Diagnostics Ltd. Installs Whole Heart Analysis System in MD Anderson Cancer Center in Houston

Ventripoint Diagnostics Ltd. Remotely Installs Whole Heart Analysis System in Major European Hospital

Ventripoint Diagnostics Ltd. Appoints Hugh MacNaught as Director of the Corporation

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure